Vitae Pharmaceuticals, Inc. (VTAE) Earns Average Broker Rating Of Outperform
By Tom Burr On March 9, 2016
Vitae Pharmaceuticals, Inc. (VTAE) is hovering around $4.5 and lots of rating firms seem to have a target price set on the stock. The median 12-month price target of 3 analysts covering the company is $22, which suggests the stock could still gain more than 389 percent. The highest analyst price target is $23, which implies a gain of 411 percent. And roundups of analyst notes show that 1 are rating the stock a buy while 3 rate VTAE a strong buy. There are 1 equity research firms suggesting a Hold and 0 consider it Sell.
According to a research note published on 04/03/2016, analysts at Stifel have lowered their rating on the company stock from Buy to Hold. According to a research note published on 29/06/2015, analysts at JMP Securities have lowered their rating on the company stock from Mkt Outperform to Mkt Perform. Stifel analysts issued their verdict on Vitae Pharmaceuticals, Inc. recently. The rating firm gave a Buy rating to this stock in a research note on 20/10/2014.
Vitae Pharmaceuticals, Inc. (VTAE) Insider Activity
Several executives took part in recent insider activity for the stock. Its Director HAYDEN DONALD J JR sold 16130 company shares for $290300, in a transaction on 29/12/2015. Following the transaction, the Director is left with a stake of 0 shares, currently valued at $0. Meanwhile, CEO
Hatfield Jeffrey S. divested 22524 shares worth $382900, through a transaction dated 23/12/2015. Following the completion of the transaction, the insider is left with a stake of 293897 shares, amounting $1322536.5. VTAE Director, HAYDEN DONALD J JR also disposed of 16130 shares, at a stock price of $17. This transaction occurred on 21/09/2015 totals $274200. After this transaction, the insider’s stake stands at 0 shares, with a market value of $0.
Vitae Pharmaceuticals, Inc. Earnings Overview
In Vitae Pharmaceuticals,’s most recent quarter, EPS grew 30 percent to $-0.52 from $-0.4 a year earlier and revenues decreased to $90000 from $180000. Analysts had expected Vitae Pharmaceuticals, Inc. to report earnings of about $-0.62 per share on $120000 in revenue. Looking forward, analysts on average predict that earnings for the current quarter would come in between $-0.62 and $-0.53. That is compared with the $-0.47 in earnings per share it reported during the same period last year.
By Tom Burr On March 9, 2016
Vitae Pharmaceuticals, Inc. (VTAE) is hovering around $4.5 and lots of rating firms seem to have a target price set on the stock. The median 12-month price target of 3 analysts covering the company is $22, which suggests the stock could still gain more than 389 percent. The highest analyst price target is $23, which implies a gain of 411 percent. And roundups of analyst notes show that 1 are rating the stock a buy while 3 rate VTAE a strong buy. There are 1 equity research firms suggesting a Hold and 0 consider it Sell.
According to a research note published on 04/03/2016, analysts at Stifel have lowered their rating on the company stock from Buy to Hold. According to a research note published on 29/06/2015, analysts at JMP Securities have lowered their rating on the company stock from Mkt Outperform to Mkt Perform. Stifel analysts issued their verdict on Vitae Pharmaceuticals, Inc. recently. The rating firm gave a Buy rating to this stock in a research note on 20/10/2014.
Vitae Pharmaceuticals, Inc. (VTAE) Insider Activity
Several executives took part in recent insider activity for the stock. Its Director HAYDEN DONALD J JR sold 16130 company shares for $290300, in a transaction on 29/12/2015. Following the transaction, the Director is left with a stake of 0 shares, currently valued at $0. Meanwhile, CEO
Hatfield Jeffrey S. divested 22524 shares worth $382900, through a transaction dated 23/12/2015. Following the completion of the transaction, the insider is left with a stake of 293897 shares, amounting $1322536.5. VTAE Director, HAYDEN DONALD J JR also disposed of 16130 shares, at a stock price of $17. This transaction occurred on 21/09/2015 totals $274200. After this transaction, the insider’s stake stands at 0 shares, with a market value of $0.
Vitae Pharmaceuticals, Inc. Earnings Overview
In Vitae Pharmaceuticals,’s most recent quarter, EPS grew 30 percent to $-0.52 from $-0.4 a year earlier and revenues decreased to $90000 from $180000. Analysts had expected Vitae Pharmaceuticals, Inc. to report earnings of about $-0.62 per share on $120000 in revenue. Looking forward, analysts on average predict that earnings for the current quarter would come in between $-0.62 and $-0.53. That is compared with the $-0.47 in earnings per share it reported during the same period last year.
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
